These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6375562)

  • 21. Pharmacokinetics of azlocillin in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Godin M; Fillastre JP
    Antimicrob Agents Chemother; 1980 Mar; 17(3):344-9. PubMed ID: 7425600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis.
    Tourkantonis A; Nicolaidis P
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():263-7. PubMed ID: 6352629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple-dose pharmacokinetics of ceftazidime in cancer patients.
    Garcia I; Fainstein V; Smith RG; Bodey GP
    Antimicrob Agents Chemother; 1983 Aug; 24(2):141-4. PubMed ID: 6357067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency.
    Kelloway JS; Awni WM; Lin CC; Lim J; Affrime MB; Keane WF; Matzke GR; Halstenson CE
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2267-74. PubMed ID: 1803999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of ceftazidime during plasmapheresis.
    Bozkurt F; Schollmeyer P; Keller E
    Eur J Clin Pharmacol; 1987; 33(2):197-201. PubMed ID: 3319644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of intermittent intraperitoneal ceftazidime.
    Grabe DW; Bailie GR; Eisele G; Frye RF
    Am J Kidney Dis; 1999 Jan; 33(1):111-7. PubMed ID: 9915275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora.
    Kemmerich B; Warns H; Lode H; Borner K; Koeppe P; Knothe H
    Antimicrob Agents Chemother; 1983 Sep; 24(3):333-8. PubMed ID: 6357074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of carumonam (AMA-1080) in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K; Suzuki H; Saruta T; Deguchi N; Fugono T
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1048-52. PubMed ID: 1929242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.
    Walstad RA; Aanderud L; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(5):543-9. PubMed ID: 3069478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-daily versus twice-daily administration of ceftazidime in the preterm infant.
    van den Anker JN; Schoemaker RC; van der Heijden BJ; Broerse HM; Neijens HJ; de Groot R
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2048-50. PubMed ID: 8540714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of cefodizime in patients with various degrees of renal failure.
    Loffreda A; Lampa E; Lucarelli C; Amorena M; Contaldi C; Calderaro V; Rossi F
    Chemotherapy; 1999; 45(1):1-7. PubMed ID: 9876203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency.
    Humbert G; Leroy A; Fillastre JP; Godin M
    Chemotherapy; 1979; 25(4):189-95. PubMed ID: 456077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations.
    Armstrong GC; Wise R; Brown RM; Hancox J
    Antimicrob Agents Chemother; 1981 Sep; 20(3):356-8. PubMed ID: 7030200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of carumonam in patients with renal insufficiency.
    Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
    Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.
    Lüthy R; Blaser J; Bonetti A; Simmen H; Wise R; Siegenthaler W
    Antimicrob Agents Chemother; 1981 Nov; 20(5):567-75. PubMed ID: 6275776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of pregabalin in subjects with various degrees of renal function.
    Randinitis EJ; Posvar EL; Alvey CW; Sedman AJ; Cook JA; Bockbrader HN
    J Clin Pharmacol; 2003 Mar; 43(3):277-83. PubMed ID: 12638396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.